Opioid-induced constipation: advances and clinical guidance

被引：78

作者：

Nelson, Alfred D. ^{[1
]}

Camilleri, Michael ^{[1
]}

机构：

[1] Mayo Clin, Div Gastroenterol & Hepatol, Clin Enter Neurosci Translat & Epidemiol Res CENT, Charlton Bldg,Room 8-110,200 First St SW, Rochester, MN 55905 USA

来源：

THERAPEUTIC ADVANCES IN CHRONIC DISEASE | 2016年 / 7卷 / 02期

关键词：

lubiprostone; methylnaltrexone; naloxegol; noncancer pain; peripheral mu opioid receptor antagonist; tolerance; CHRONIC NONCANCER PAIN; PROLONGED-RELEASE OXYCODONE; INDUCED BOWEL DYSFUNCTION; PLACEBO-CONTROLLED TRIAL; QUATERNARY NARCOTIC-ANTAGONISTS; RECOMBINANT HUMAN CLC-2; DOUBLE-BLIND; HEALTHY-VOLUNTEERS; SUBCUTANEOUS METHYLNALTREXONE; GASTROINTESTINAL TRANSIT;

D O I：

10.1177/2040622315627801

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most common adverse effect associated with prolonged use of opioids, having a major impact on quality of life. There is an increasing need to treat opioid-induced constipation. With the recent approval of medications for the treatment of opioid-induced constipation, there are several therapeutic approaches. This review addresses the clinical presentation and diagnosis of opioid-induced constipation, barriers to its diagnosis, effects of opioids in the gastrointestinal tract, differential tolerance to opiates in different gastrointestinal organs, medications approved and in development for the treatment of opioid-induced constipation, and a proposed clinical management algorithm for treating opioid-induced constipation in patients with noncancer pain.

引用

页码：121 / 134

页数：14

共 91 条

[1] Site and mechanism of morphine tolerance in the gastrointestinal tract
Akbarali, H. I.
Inkisar, A.
Dewey, W. L.
[J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (10) : 1361 - 1367
[2] AMIN HM, 1994, ANESTH ANALG, V78, P701
[3] Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation
Argoff, Charles E.
Brennan, Michael J.
Camilleri, Michael
Davies, Andrew
Fudin, Jeffrey
Galluzzi, Katherine E.
Gudin, Jeffrey
Lembo, Anthony
Stanos, Steven P.
Webster, Lynn R.
[J]. PAIN MEDICINE, 2015, 16 (12) : 2324 - 2337
[4] The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity
Armstrong, Scott R.
Campbell, Christina B.
Richardson, Carrie L.
Vickery, Ross G.
Tsuruda, Pamela R.
Long, Daniel D.
Hegde, Sharath S.
Beattie, David T.
[J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (06) : 471 - 478
[5] Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract
Bagnol, D
Mansour, A
Akil, H
Watson, SJ
[J]. NEUROSCIENCE, 1997, 81 (02) : 579 - 591
[6] The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)
Bell, Timothy J.
Panchal, Sunil J.
Miaskowski, Christine
Bolge, Susan C.
Milanova, Tsveta
Williamson, Russell
[J]. PAIN MEDICINE, 2009, 10 (01) : 35 - 42
[7] Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105
[8] Activation of Intestinal Cl- Secretion by Lubiprostone Requires the Cystic Fibrosis Transmembrane Conductance Regulator
Bijvelds, Marcel J. C.
Bot, Alice G. M.
Escher, Johanna C.
de Jonge, Hugo R.
[J]. GASTROENTEROLOGY, 2009, 137 (03) : 976 - 985
[9] Enhanced morphine analgesia in mice lacking β-arrestin 2
Bohn, LM
Lefkowitz, RJ
Gainetdinov, RR
Peppel, K
Caron, MG
Lin, FT
[J]. SCIENCE, 1999, 286 (5449) : 2495 - 2498
[10] THE USE OF QUATERNARY NARCOTIC-ANTAGONISTS IN OPIATE RESEARCH
BROWN, DR
GOLDBERG, LI
[J]. NEUROPHARMACOLOGY, 1985, 24 (03) : 181 - 191

← 1 2 3 4 5 6 7 8 9 10 →